search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Advanced Glycation End Products in Patients with Peripheral Arterial Occlusive Disease or Abdominal Aortic Aneurysm


- candidate number22747
- NTR NumberNTR5363
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-aug-2015
- Secondary IDsNL45660.042.14 METc2014-269
- Public TitleAdvanced Glycation End Products in Patients with Peripheral Arterial Occlusive Disease or Abdominal Aortic Aneurysm
- Scientific TitleAdvanced Glycation End Products in Patients with Peripheral Arterial Occlusive Disease or Abdominal Aortic Aneurysm
- ACRONYMARTERY
- hypothesisThe primary objective is to compare the amount and types of AGEs of the arterial wall of both PAOD and AAA in patients with and without DM.
- Healt Condition(s) or Problem(s) studiedAbdominal Aortic Aneurysm, Peripheral arterial disease (PAD), Diabetes Mellitus
- Inclusion criteriaAge > 18 years old.
AAA or PAOD
Scheduled for open surgical repair of an AAA or bypass surgery or endarterectomy for PAOD.
- Exclusion criteriaBoth AAA and PAOD
Inflammatory disease (rheumatoid artritis, SLE, giant cell artritis, Takayasu disease)
Inflammatory/mycotic aneurysm
Connective tissue disease (Marfans disease/ Ehlers-Danlos disease)
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeobservational
- planned startdate 1-okt-2015
- planned closingdate1-okt-2017
- Target number of participants120
- InterventionsNone
- Primary outcomeAdvanced glycation end products in the arterial wall
- Secondary outcomeSerum, urine and skin AGEs (measured by SAF).
Mechanical properties of the arterial wall.
Serum, urine and tissue markers of inflammation and oxidative stress
- TimepointsVisit before surgery: vascular lab + laboratory for blood and urine.
Return 24h urine.
Surgery
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. J.D. Lefrandt
- CONTACT for SCIENTIFIC QUERIESDr. J.D. Lefrandt
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
University of Groningen
- Publications
- Brief summaryPeripheral arterial occlusive disease (PAOD) and abdominal aortic aneurysms (AAA) are thought to have different pathophysiology. PAOD and AAA share smoking as major risk factor. However, DM is a common risk factor for occlusive vascular disease, but a protective factor for dilating disease. Accumulation of advanced glycation end products (AGEs) in the arterial wall could possibly explain the different effects of DM on these diseases. AGEs are sugar-modified moieties forming on proteins which are formed under influence of oxidative and glycemic stress. AGEs have the potential to create cross-links and to induce inflammatory and oxidative stress responses after binding to the receptor for AGE. Increased accumulation of AGEs is associated with increased risk of cardiovascular morbidity and mortality in several diseases, including PAOD.
- Main changes (audit trail)
- RECORD14-aug-2015 - 17-okt-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl